The side effects of ACEIs and ARBs may be resulting in less frequent use in a population that could benefit from these medications. A new study found that continuous ACEI/ARB use prior to dialysis ...

High blood pressure and cardiovascular and renal diseases are often treated with a combination of renin-angiotensin-aldosterone system inhibitors. However, as these agents have the potential to cause ...

Antihypertensive regimens that include a mineralocorticoid receptor antagonist carry the highest risk for hyperkalemia. Among the drug combinations that may increase serum potassium in patients with ...

In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...

The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi. In patients with diabetic kidney disease, use of 2 classes of renin-angiotensin-aldosterone system ...

The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac conduction ...

OBJECTIVES: Many patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) experience a delay in treatment or fail to initiate treatment with guideline-recommended angiotensin-converting ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes who began GLP-1 therapy were less likely to develop hyperkalemia than adults ...